The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.
Lentiviral vectors: basic to translational
Abstract
More than two decades have passed since genetically modified HIV was used for gene delivery. Through continuous improvements these early marker gene-carrying HIVs have evolved into safer and more effective lentiviral vectors. Lentiviral vectors offer several attractive properties as gene-delivery vehicles, including: (i) sustained gene delivery through stable vector integration into host genome; (ii) the capability of infecting both dividing and non-dividing cells; (iii) broad tissue tropisms, including important gene- and cell-therapy-target cell types; (iv) no expression of viral proteins after vector transduction; (v) the ability to deliver complex genetic elements, such as polycistronic or intron-containing sequences; (vi) potentially safer integration site profile; and (vii) a relatively easy system for vector manipulation and production. Accordingly, lentivector technologies now have widespread use in basic biology and translational studies for stable transgene overexpression, persistent gene silencing, immunization, in vivo imaging, generating transgenic animals, induction of pluripotent cells, stem cell modification and lineage tracking, or site-directed gene editing. Moreover, in the present high-throughput ‘-omics’ era, the commercial availability of premade lentiviral vectors, which are engineered to express or silence genome-wide genes, accelerates the rapid expansion of this vector technology. In the present review, we assess the advances in lentiviral vector technology, including basic lentivirology, vector designs for improved efficiency and biosafety, protocols for vector production and infection, targeted gene delivery, advanced lentiviral applications and issues associated with the vector system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–228 of 228
Terwilliger, E., Godin, B., Sodroski, J., & Haseltine, W. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3857 · Cited by 60
Ginn, S. L., Liao, S. H. Y., Dane, A. P., Hu, M., Hyman, J., Finnie, J. W., Zheng, M., Cavazzana, M., Alexander, S. I., Thrasher, A. J., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.50 · Cited by 59
Chen, W., Wu, X., Levasseur, D. N., Liu, H., Lai, L., Kappes, J. C., & Townes, T. M. (2000) · Stem Cells · doi:10.1634/stemcells.18-5-352 · Cited by 58
Evolutionary origin of human and simian immunodeficiency viruses.
Gojobori, T., Moriyama, E. N., Ina, Y., Ikeo, K., Miura, T., Tsujimoto, H., Hayami, M., & Yokoyama, S. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4108 · Cited by 57
Iyer, M. R., Salazar, F. B., Lewis, X., Zhang, L., Carey, M., Wu, L., & Gambhir, S. S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.06.118 · Cited by 56
Multigene Lentiviral Vectors Based on Differential Splicing and Translational Control
Zhu, Y., Feuer, G., Day, S. L., Wrzesinski, S. H., & Planelles, V. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0469 · Cited by 54
HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells
Dai, B., Yang, L., Yang, H., Hu, B., Baltimore, D., & Wang, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911742106 · Cited by 53
Licursi, M., Christian, S. L., Pongnopparat, T., & Hirasawa, K. (2011) · Gene Therapy · doi:10.1038/gt.2011.11 · Cited by 52
Benabdellah, K., Cobo, M., Muñoz, P., Toscano, M. G., & Martín, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023734 · Cited by 48
Relander, T., Johansson, M., Olsson, K., Ikeda, Y., Takeuchi, Y., Collins, M. K., & Richter, J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.10.014 · Cited by 47
Self-citationIn vivo correction of ZAP-70 immunodeficiency by intrathymic gene transfer.
Adjali, O., Marodon, G., Steinberg, M., Mongellaz, C., Thomas-Vaslin, V., Jacquet, C., Taylor, N., & Klatzmann, D. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23966 · Cited by 46
Langley, R. J., Hirsch, V. M., O’Brien, S. J., Adger-Johnson, D., Goeken, R. M., & Olmsted, R. A. (1994) · Virology · doi:10.1006/viro.1994.1407 · Cited by 45
Strang, B. L., Takeuchi, Y., Relander, T., Richter, J., Bailey, R., Sanders, D. A., Collins, M. K., & Ikeda, Y. (2005) · Journal of Virology · doi:10.1128/jvi.79.3.1765-1771.2005 · Cited by 44
Self-citationMalik, P., Arumugam, P. I., Yee, J.-K., & Puthenveetil, G. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1345.030 · Cited by 44
Ohmine, S., Dietz, A. B., Deeds, M. C., Hartjes, K. A., Miller, D. R., Thatava, T., Sakuma, T., Kudva, Y. C., & Ikeda, Y. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt87 · Cited by 41
Self-citationRational development of a HIV‐1 gene therapy vector
Anson, D. S., & Fuller, M. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.415 · Cited by 40
Stable Transduction of Primary Human Monocytes by Simian Lentiviral Vector PBj
Mühlebach, M. D., Wolfrum, N., Schüle, S., Tschulena, U., Sanzenbacher, R., Flory, E., Cichutek, K., & Schweizer, M. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.06.483 · Cited by 40
Characterization and detection of artificial replication-competent lentivirus of altered host range
Segall, H., Yoo, E., & Sutton, R. E. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00134-5 · Cited by 39
Gallo, P., Grimaldi, S., Latronico, M. V. G., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303017 · Cited by 38
Ikeda, Y., 朝長, 啓., Kawaguchi, Y., Kohmoto, M., Inoshima, Y., Tohya, Y., Miyazawa, T., Kai, C., & Mikami, T. (1996) · Journal of General Virology · doi:10.1099/0022-1317-77-8-1623 · Cited by 38
Self-citationUchida, N., Washington, K. N., Lap, C. J. G., Hsieh, M. M., & Tisdale, J. F. (2010) · Molecular Therapy · doi:10.1038/mt.2010.218 · Cited by 37
Sakuma, T., Ravin, S. S. D., Tonne, J. M., Thatava, T., Ohmine, S., Takeuchi, Y., Malech, H. L., & Ikeda, Y. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.063 · Cited by 29
Self-citationNaumann, N., Ravin, S. S. D., Choi, U., Moayeri, M., Whiting‐Theobald, N., Linton, G. F., Ikeda, Y., & Malech, H. L. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303010 · Cited by 26
Self-citationHu, B., Yang, H., Dai, B., Tai, A., & Wang, P. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.012 · Cited by 26
Yang, H., Hu, B., Xiao, L., & Wang, P. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.13 · Cited by 24
Gilham, D. E., Lie‐A‐Ling, M., Taylor, N. N., & Hawkins, R. E. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1421 · Cited by 22
Matukonis, M. K., Li, M., Molina, R. P., Paszkiet, B., Kaleko, M., & Luo, T. (2002) · Human Gene Therapy · doi:10.1089/104303402760128522 · Cited by 19
An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization
Lemiale, F., Asefa, B., Ye, D., Chen, C., Korokhov, N., & Humeau, L. M. P. F. (2010) · Vaccine · doi:10.1016/j.vaccine.2009.10.089 · Cited by 12
Cited by
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
Gene therapy: Comprehensive overview and therapeutic applications
Sayed, N., Allawadhi, P., Khurana, A., Singh, V., Navik, U., Pasumarthi, S. K., Khurana, I., Banothu, A. K., Weiskirchen, R., & Bharani, K. K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120375 · Cited by 337
(2013) · PubMed · Cited by 308
Betibeglogene Autotemcel Gene Therapy for Non–β 0 /β 0 Genotype β-Thalassemia
Locatelli, F., Thompson, A. A., Kwiatkowski, J. L., Porter, J. B., Thrasher, A. J., Hongeng, S., Sauer, M. G., Thuret, I., Lal, A., Algeri, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2113206 · Cited by 283
Challenges and new technologies in adoptive cell therapy
Zhang, P., Zhang, G., & Wan, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01492-8 · Cited by 259
Metadata
- Authors
- Sakuma, T., Barry, M. A., & Ikeda, Y.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2012-04-16
- Volume
- 443
- Issue
- 3
- Pages
- 603-618
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W2140344320
- Cited by
- 336
- References
- 228
- FWCI
- 17.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.